Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailoring Therapy Using ctDNA in Advanced/Metastatic Colorectal Cancer (TACT-D)
NCT03844620Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib and trifluridine + tipiracil in colorectal cancer (CRC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Early change in circulating tumor-derived deoxyribonucleic acid (ctDNA) at 4 months and Treatment-related adverse events of interest at 4 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
regorafenibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03844620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844620.